32
https://pubmed.ncbi.nlm.nih.gov/38115619
Tebentafusp is a promising new drug for treating uveal melanoma, the most common primary intraocular cancer in adults, as it is the first T cell receptor (TCR) therapeutic drug approved by the FDA, with proven efficacy in clinical trials and manageable adverse effects.
